Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication
Artículo científico (JournalArticle)
Discovery of V-0219: a small-molecule positive allosteric modulator of the Glucagon-Like Peptide-1 Receptor toward oral treatment for “diabesity”
Peptidic agonists of the glucagon-like peptide-1 receptor (GLP-1R) have gained a prominent role in the therapy of type-2 diabetes and are being considered for reducing food intake in obesity. Potential advantages of small molecules acting as positive allosteric modulators (PAMs) of GLP-1R, including oral administration and reduced unwanted effects, could improve the utility of this class of drugs. Here, we describe the discovery of compound 9 (4-{[1-({3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}methyl)piperidin-3-yl]methyl}morpholine, V-0219) that exhibits enhanced efficacy of GLP-1R stimulation, subnanomolar potency in the potentiation of insulin secretion, and no significant off-target activities. The identified GLP-1R PAM shows a remarkable in vivo activity, reducing food intake and improving glucose handling in normal and diabetic rodents. Enantioselective synthesis revealed oral efficacy for (S)-9 in animal models. Compound 9 behavior bolsters the interest of a small-molecule PAM of GLP-1R as a promising therapeutic approach for the increasingly prevalent obesity-associated diabetes
Project:
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 SAF2016-78792-R
,
Agencia Estatal de Investigación / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2019-106279RB-I00
View at: https://hdl.handle.net/10347/45118